The role of IGF-1 receptor and insulin receptor signaling for the pathogenesis of Alzheimer's disease: From model organisms to human disease

Current Alzheimer Research

Volumn 6, Issue 3, 2009, Pages 213-223

  Freude, S ^a   Schilbach, K ^a   Schubert, M ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Alzheimer's disease; IGF 1 receptor; Insulin receptor

Indexed keywords

ALPHA SECRETASE; AMYLOID BETA PROTEIN[1-42]; BETA SECRETASE; GROWTH HORMONE; IBUTAMOREN; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CLINICAL TRIAL; DISEASE SEVERITY; ENZYME ACTIVITY; HORMONE ACTION; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LEARNING; LIFESPAN; LONGEVITY; MEMORY; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVIEW; SENILE PLAQUE; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MODELS, BIOLOGICAL; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION; TAU PROTEINS;

EID: 67149139990     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720509788486527     Document Type: Review

References (160)

1. Citron M. Alzheimer's disease: treatments in discovery and development. Nat Neurosci 5 (Suppl): 1055-1057 (2002). (Pubitemid 35247198)
2. Cole AR, Astell A, Green C, Sutherland C. Molecular connexions between dementia and diabetes. Neurosci Biobehav Rev 31: 1046-1063 (2007). (Pubitemid 47332620)
3. Tschanz JT, Corcoran C, Skoog I, Khachaturian AS, Herrick J, Hayden KM, et al. Dementia: the leading predictor of death in a defined elderly population: the Cache County Study. Neurology 62: 1156-1162 (2004).
4. Treiber KA, Lyketsos CG, Corcoran C, Steinberg M, Norton M, Green RC, et al. Vascular factors and risk for neuropsychiatric symptoms in Alzheimer's disease: the Cache County Study. Int Psychogeriatr 20: 538-553 (2008).
5. Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53: 474-481 (2004). (Pubitemid 38174565)
6. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 53: 1937-1942 (1999).
7. Stewart R, Liolitsa D. Type 2 diabetes mellitus, cognitive impairment and dementia. Diabet Med 16: 93-112 (1999).
8. Lovestone S. Diabetes and dementia: is the brain another site of end-organ damage? Neurology 53: 1907-1909 (1999).
9. Ott A, Stolk RP, Hofman A, van Harskamp F, Grobbee DE, Breteler MM. Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia 39: 1392-1397 (1996). (Pubitemid 26356072)
10. Luchsinger JA, Tang MX, Shea S and Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 63: 1187-1192 (2004).
11. Ronnemaa E, Zethelius B, Sundelof J, Sundstrom J, Degerman-Gunnarsson M, Berne C, et al. Impaired insulin secretion increases the risk of Alzheimer disease. Neurology (2008) [Epub ahead print].
12. Pluta R. Blood-brain barrier dysfunction and amyloid precursor protein accumulation in microvascular compartment following ischemia-reperfusion brain injury with 1-year survival. Acta Neurochir Suppl 86: 117-122 (2003).
13. Sadowski M, Pankiewicz J, Scholtzova H, Li YS, Quartermain D, Duff K, et al. Links between the pathology of Alzheimer's disease and vascular dementia. Neurochem Res 29: 1257-1266 (2004).
14. de la Monte SM, Wands JR. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J Alzheimers Dis 7: 45-61 (2005). (Pubitemid 40387184)
15. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease - is this type 3 diabetes? J Alzheimers Dis 7: 63-80 (2005).
16. Van Obberghen E, Ksauga M, Le Cam A, Hedo JA, Itin A, Harrison LC. Biosynthetic labeling of insulin receptor: studies of subunits in cultured human IM-9 lymphocytes. Proc Natl Acad Sci USA 78: 1052-1056 (1981). (Pubitemid 11100768)
17. Kasuga M, Fujita-Yamaguchi Y, Blithe DL and Kahn CR. Tyrosine-specific protein kinase activity is associated with the purified insulin receptor. Proc Natl Acad Sci USA 80: 2137-2141 (1983).
18. Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C, et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 5: 2503-2512 (1986).
19. Chou CK, Dull TJ, Russell DS, Gherzi R, Lebwohl D, Ullrich A, et al. Human insulin receptors mutated at the ATP-binding site lack protein tyrosine kinase activity and fail to mediate postreceptor effects of insulin. J Biol Chem 262: 1842-1847 (1987).
20. Ebina Y. [Molecular biology of insulin receptors]. Nippon Naibunpi Gakkai Zasshi 63: 1415-1417 (1987).
21. White MF. Regulating insulin signaling and beta-cell function through IRS proteins. Can J Physiol Pharmacol 84: 725-737 (2006). (Pubitemid 44897893)
22. Kahn CR, Baird KL, Jarrett DB, Flier JS. Direct demonstration that receptor crosslinking or aggregation is important in insulin action. Proc Natl Acad Sci USA 75: 4209-4213 (1978). (Pubitemid 9025979)
23. Sun XJ, Rothenberg P, Kahn CR, Backer JM, Araki E, Wilden PA, et al. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 352: 73-77 (1991).
24. Lavan BE, Fantin VR, Chang ET, Lane WS, Keller SR, Lienhard GE. A novel 160-kDa phosphotyrosine protein in insulin-treated embryonic kidney cells is a new member of the insulin receptor substrate family. J Biol Chem 272: 21403-21407 (1997). (Pubitemid 27374010)
25. Lavan BE, Lane WS, Lienhard GE. The 60-kDa phosphotyrosine protein in insulin-treated adipocytes is a new member of the insulin receptor substrate family. J Biol Chem 272: 11439-11443 (1997). (Pubitemid 27184151)
26. Giovannone B, Scaldaferri ML, Federici M, Porzio O, Lauro D, Fusco A, et al. Insulin receptor substrate (IRS) transduction system: distinct and overlapping signaling potential. Diabetes Metab Res Rev 16: 434-441 (2000).
27. Schubert M, Brazil DP, Burks DJ, Kushner JA, Ye J, Flint CL, et al. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J Neurosci 23: 7084-7092 (2003).
28. Numan S, Russell DS. Discrete expression of insulin receptor substrate-4 mRNA in adult rat brain. Brain Res Mol Brain Res 72: 97-102 (1999). (Pubitemid 29474919)
29. Partridge L, Bruning JC. Forkhead transcription factors and ageing. Oncogene 27: 2351-2363 (2008).
30. Naimi M, Gautier N, Chaussade C, Valverde AM, Accili D, Van Obberghen E. Nuclear forkhead box O1 controls and integrates key signaling pathways in hepatocytes. Endocrinology 148: 2424-2434 (2007). (Pubitemid 46997056)
31. Frescas D, Valenti L, Accili D. Nuclear trapping of the forkhead transcription factor FoxO1 via Sirt-dependent deacetylation pro motes expression of glucogenetic genes. J Biol Chem 280: 20589-20595 (2005). (Pubitemid 40776761)
32. Calnan DR, Brunet A. The FoxO code. Oncogene 27: 2276-2288 (2008).
33. Curtis C, Landis GN, Folk D, Wehr NB, Hoe N, Waskar M, et al. Transcriptional profiling of MnSOD-mediated lifespan extension in Drosophila reveals a species-general network of aging and metabolic genes. Genome Biol 8: R262 (2007).
34. Chavez V, Mohri-Shiomi A, Maadani A, Vega LA, Garsin DA. Oxidative stress enzymes are required for DAF-16-mediated immunity due to generation of reactive oxygen species by Caenorhabditis elegans. Genetics 176: 1567-1577 (2007).
35. Cohen E, Bieschke J, Perciavalle RM, Kelly JW, Dillin A. Opposing activities protect against age-onset proteotoxicity. Science 313: 1604-1610 (2006). (Pubitemid 44414028)
36. Astrinidis A, Henske EP. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. Oncogene 24: 7475-7481 (2005). (Pubitemid 41637987)
37. Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 351 (Pt 2): 289-305 (2000). (Pubitemid 30825590)
38. Sweatt JD. The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. J Neurochem 76: 1-10 (2001).
39. Zhuang S, Schnellmann RG. A death-promoting role for extracellular signal-regulated kinase. J Pharmacol Exp Ther 319: 991-997 (2006). (Pubitemid 44776445)
40. Saba-El-Leil MK, Vella FD, Vernay B, Voisin L, Chen L, Labrecque N, et al. An essential function of the mitogen-activated protein kinase Erk2 in mouse trophoblast development. EMBO Rep 4: 964-968 (2003).
41. Havrankova J, Roth J, Brownstein M. Insulin receptors are widely distributed in the central nervous system of the rat. Nature 272: 827-829 (1978). (Pubitemid 8316991)
42. Hill JM, Lesniak MA, Pert CB, Roth J. Autoradiographic localization of insulin receptors in rat brain: prominence in olfactory and limbic areas. Neuroscience 17: 1127-1138 (1986). (Pubitemid 16080101)
43. van Houten M, Posner BI. Insulin binds to brain blood vessels in vivo. Nature 282: 623-625 (1979). (Pubitemid 10213922)
44. van Houten M, Posner BI. Circumventricular organs: receptors and mediators of direct peptide hormone action on brain. Adv Metab Disord 10: 269-289 (1983).
45. Baskin DG, Davidson D, Corp ES, Lewellen T, Graham M. An inexpensive microcomputer digital imaging system for densitometry: quantitative autoradiography of insulin receptors with 125I and LKB Ultrofilm. J Neurosci Methods 16: 119-129 (1986). (Pubitemid 16069078)
46. Unger J, McNeill TH, Moxley RT, III, White M, Moss A, Livingston JN. Distribution of insulin receptor-like immunoreactivity in the rat forebrain. Neuroscience 31: 143-157 (1989). (Pubitemid 19209704)
47. Werther GA, Hogg A, Oldfield BJ, McKinley MJ, Figdor R, Allen AM, et al. Localization and characterization of insulin receptors in rat brain and pituitary gland using in vitro autoradiography and computerized densitometry. Endocrinology 121: 1562-1570 (1987).
48. Rotwein P, Burgess SK, Milbrandt JD, Krause JE. Differential expression of insulin-like growth factor genes in rat central nervous system. Proc Natl Acad Sci USA 85: 265-269 (1988). (Pubitemid 18055327)
49. Garcia-Segura LM, Rodriguez JR, Torres-Aleman I. Localization of the insulin-like growth factor I receptor in the cerebellum and hypothalamus of adult rats: an electron microscopic study. J Neurocytol 26: 479-490 (1997). (Pubitemid 27382102)
50. Lesniak MA, Hill JM, Kiess W, Rojeski M, Pert CB, Roth J. Receptors for insulin-like growth factors I and II: autoradiographic localization in rat brain and comparison to receptors for insulin. Endocrinology 123: 2089-2099 (1988). (Pubitemid 18243828)
51. Bondy CA, Werner H, Roberts CT, Jr., LeRoith D. Cellular pattern of insulin-like growth factor-I (IGF-I) and type I IGF receptor gene expression in early organogenesis: comparison with IGF-II gene expression. Mol Endocrinol 4: 1386-1398 (1990). (Pubitemid 20371439)
52. Schulingkamp RJ, Pagano TC, Hung D, Raffa RB. Insulin receptors and insulin action in the brain: review and clinical implications. Neurosci Biobehav Rev 24: 855-872 (2000).
53. Chung YH, Shin CM, Joo KM, Kim MJ, Cha CI. Region-specific alterations in insulin-like growth factor receptor type I in the cerebral cortex and hippocampus of aged rats. Brain Res 946: 307-313 (2002). (Pubitemid 34876344)
54. Frolich L, Blum-Degen D, Bernstein HG, Engelsberger S, Humrich J, Laufer S, et al. Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm 105: 423-438 (1998).
55. Carro E, Trejo JL, Gomez-Isla T, LeRoith D, Torres-Aleman I. Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat Med 8: 1390-1397 (2002). (Pubitemid 36019424)
56. Banks WA, Kastin AJ. Peptides and the blood-brain barrier: lipophilicity as a predictor of permeability. Brain Res Bull 15: 287-292 (1985). (Pubitemid 16229709)
57. Broadwell RD, Sofroniew MV. Serum proteins bypass the bloodbrain fluid barriers for extracellular entry to the central nervous system. Exp Neurol 120: 245-263 (1993). (Pubitemid 23165019)
58. Baura GD, Foster DM, Porte D, Jr., Kahn SE, Bergman RN, Cobelli C, et al. Saturable transport of insulin from plasma into the central nervous system of dogs in vivo. A mechanism for regulated insulin delivery to the brain. J Clin Invest 92: 1824-1830 (1993).
59. King GL, Johnson SM. Receptor-mediated transport of insulin across endothelial cells. Science 227: 1583-1586 (1985). (Pubitemid 15119466)
60. Schwartz MW, Sipols A, Kahn SE, Lattemann DF, Taborsky GJ, Jr., Bergman RN, et al. Kinetics and specificity of insulin uptake from plasma into cerebrospinal fluid. Am J Physiol 259: E378-E383 (1990).
61. Banks WA, Jaspan JB, Huang W, Kastin AJ. Transport of insulin across the blood-brain barrier: saturability at euglycemic doses of insulin. Peptides 18: 1423-1429 (1997). (Pubitemid 27519755)
62. Jialal I, King GL, Buchwald S, Kahn CR, Crettaz M. Processing of insulin by bovine endothelial cells in culture. Internalization without degradation. Diabetes 33: 794-800 (1984).
63. Pardridge WM. Receptor-mediated peptide transport through the blood-brain barrier. Endocr Rev 7: 314-330 (1986).
64. Porte D, Jr., Seeley RJ, Woods SC, Baskin DG, Figlewicz DP, Schwartz MW. Obesity, diabetes and the central nervous system. Diabetologia 41: 863-881 (1998). (Pubitemid 28365972)
65. Freude S, Plum L, Schnitker J, Leeser U, Udelhoven M, Krone W, et al. Peripheral hyperinsulinemia promotes tau phosphorylation in vivo. Diabetes 54: 3343-3348 (2005). (Pubitemid 43334322)
66. Banks WA, Kastin AJ. Differential permeability of the blood-brain barrier to two pancreatic peptides: insulin and amylin. Peptides 19: 883-889 (1998). (Pubitemid 28312286)
67. Banks WA, During MJ, Niehoff ML. Brain uptake of the glucagonlike peptide-1 antagonist exendin(9-39) after intranasal administration. J Pharmacol Exp Ther 309: 469-475 (2004). (Pubitemid 38542596)
68. Kern W, Born J, Schreiber H, Fehm HL. Central nervous system effects of intranasally administered insulin during euglycemia in men. Diabetes 48: 557-563 (1999). (Pubitemid 29106869)
69. Baskin DG, Stein LJ, Ikeda H, Woods SC, Figlewicz DP, Porte D Jr., et al. Genetically obese Zucker rats have abnormally low brain insulin content. Life Sci 36: 627-633 (1985).
70. Strubbe JH, Porte D, Jr., Woods SC. Insulin responses and glucose levels in plasma and cerebrospinal fluid during fasting and refeeding in the rat. Physiol Behav 44: 205-208 (1988). (Pubitemid 18261209)
71. Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D, Jr. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 50: 164-168 (1998).
72. Baura GD, Foster DM, Kaiyala K, Porte D, Jr., Kahn SE, Schwartz MW. Insulin transport from plasma into the central nervous system is inhibited by dexamethasone in dogs. Diabetes 45: 86-90 (1996). (Pubitemid 26010428)
73. Pan W, Kastin AJ. Interactions of IGF-1 with the blood-brain barrier in vivo and in situ. Neuroendocrinology 72: 171-178 (2000).
74. Reinhardt RR, Bondy CA. Insulin-like growth factors cross the blood-brain barrier. Endocrinology 135: 1753-1761 (1994). (Pubitemid 24363863)
75. Yu Y, Kastin AJ, Pan W. Reciprocal interactions of insulin and insulin-like growth factor I in receptor-mediated transport across the blood-brain barrier. Endocrinology 147: 2611-2615 (2006). (Pubitemid 43764592)
76. Frolich L, Blum-Degen D, Riederer P, Hoyer S. A disturbance in the neuronal insulin receptor signal transduction in sporadic Alzheimer's disease. Ann N Y Acad Sci 893: 290-293 (1999). (Pubitemid 30038089)
77. Moloney AM, Griffin RJ, Timmons S, O'Connor R, Ravid R, O'Neill C. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging (2008) [Epub ahead of print].
78. Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis 8: 247-268 (2005). (Pubitemid 43312053)
79. Vardy ER, Rice PJ, Bowie PC, Holmes JD, Grant PJ, Hooper NM. Increased circulating insulin-like growth factor-1 in late-onset Alzheimer's disease. J Alzheimers Dis 12: 285-290 (2007).
80. Townsend M, Mehta T, Selkoe DJ. Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem 282: 33305-33312 (2007). (Pubitemid 350159548)
81. Xie L, Helmerhorst E, Taddei K, Plewright B, Van Bronswijk W, Martins R. Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor. J Neurosci 22: RC221 (2002).
82. Zhao WQ, De Felice FG, Fernandez S, Chen H, Lambert MP, Quon MJ, et al. Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J 22: 246-260 (2008).
83. Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol 490: 115-125 (2004). (Pubitemid 38482165)
84. Watson GS, Craft S. Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease. Eur J Pharmacol 490: 97-113 (2004). (Pubitemid 38482164)
85. Squire LR. Mechanisms of memory. Science 232: 1612-1619 (1986). (Pubitemid 16095600)
86. Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 3: 169-178 (2004). (Pubitemid 38229951)
87. Zhao W, Chen H, Xu H, Moore E, Meiri N, Quon MJ, et al. Brain insulin receptors and spatial memory. Correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze trained rats. J Biol Chem 274: 34893-34902 (1999).
88. Svensson J, Diez M, Engel J, Wass C, Tivesten A, Jansson JO, et al. Endocrine, liver-derived IGF-I is of importance for spatial learning and memory in old mice. J Endocrinol 189: 617-627 (2006).
89. Dik MG, Pluijm SM, Jonker C, Deeg DJ, Lomecky MZ, Lips P. Insulin-like growth factor I (IGF-I) and cognitive decline in older persons. Neurobiol Aging 24: 573-581 (2003). (Pubitemid 36513705)
90. Schubert M, Gautam D, Surjo D, Ueki K, Baudler S, Schubert D, et al. Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci USA 101: 3100-3105 (2004).
91. Hallschmid M, Schultes B, Marshall L, Molle M, Kern W, Bredthauer J, et al. Transcortical direct current potential shift reflects immediate signaling of systemic insulin to the human brain. Diabetes 53: 2202-2208 (2004).
92. Young SE, Mainous AG, III, Carnemolla M. Hyperinsulinemia and cognitive decline in a middle-aged cohort. Diabetes Care 29: 2688-2693 (2006).
93. Peila R, Rodriguez BL, White LR, Launer LJ. Fasting insulin and incident dementia in an elderly population of Japanese-American men. Neurology 63: 228-233 (2004). (Pubitemid 38971119)
94. Craft S, Newcomer J, Kanne S, Dagogo-Jack S, Cryer P, Sheline Y, et al. Memory improvement following induced hyperinsulinemia in Alzheimer's disease. Neurobiol Aging 17: 123-130 (1996).
95. Kern W, Peters A, Fruehwald-Schultes B, Deininger E, Born J, Fehm HL. Improving influence of insulin on cognitive functions in humans. Neuroendocrinology 74: 270-280 (2001). (Pubitemid 34701752)
96. Benedict C, Hallschmid M, Schultes B, Born J, Kern W. Intranasal insulin to improve memory function in humans. Neuroendocrinology 86: 136-142 (2007). (Pubitemid 47494214)
97. Benedict C, Kern W, Schultes B, Born J, Hallschmid M. Differential sensitivity of men and women to anorexigenic and memory-improving effects of intranasal insulin. J Clin Endocrinol Metab 93: 1339-1344 (2008).
98. Benedict C, Hallschmid M, Hatke A, Schultes B, Fehm HL, Born J, et al. Intranasal insulin improves memory in humans. Psychoneuroendocrinology 29: 1326-1334 (2004).
99. Clegg DJ, Brown LM, Woods SC, Benoit SC. Gonadal hormones determine sensitivity to central leptin and insulin. Diabetes 55: 978-987 (2006). (Pubitemid 44100172)
100. Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 70: 440-448 (2008).
101. Tschritter O, Preissl H, Hennige AM, Stumvoll M, Porubska K, Frost R, et al. The cerebrocortical response to hyperinsulinemia is reduced in overweight humans: a magnetoencephalographic study. Proc Natl Acad Sci USA 103: 12103-12108 (2006).
102. Avila J, Diaz-Nido J. Tangling with hypothermia. Nat Med 10: 460-461 (2004). (Pubitemid 38667901)
103. Avila J. Tau kinases, phosphatases. J Cell Mol Med 12: 258-259 (2008).
104. Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci 22: 1942-1950 (2005). (Pubitemid 41579384)
105. Liu R, Zhou XW, Tanila H, Bjorkdahl C, Wang JZ, Guan ZZ, et al. Phosphorylated PP2A (tyrosine 307) is associated with Alzheimer neurofibrillary pathology. J Cell Mol Med 12: 241-257 (2008).
106. Flaherty DB, Soria JP, Tomasiewicz HG, Wood JG. Phosphorylation of human tau protein by microtubule-associated kinases: GSK3beta and cdk5 are key participants. J Neurosci Res 62: 463-472 (2000). (Pubitemid 30822728)
107. Cho JH, Johnson GV. Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3beta (GSK3beta) plays a critical role in regulating tau's ability to bind and stabilize microtubules. J Neurochem 88: 349-358 (2004). (Pubitemid 38084551)
108. Jamsa A, Hasslund K, Cowburn RF, Backstrom A, Vasange M. The retinoic acid and brain-derived neurotrophic factor differentiated SH-SY5Y cell line as a model for Alzheimer's disease-like tau phosphorylation. Biochem Biophys Res Commun 319: 993-1000 (2004). (Pubitemid 38739418)
109. Stoothoff WH, Johnson GV. Tau phosphorylation: physiological and pathological consequences. Biochim Biophys Acta 1739: 280-297 (2005). (Pubitemid 40018545)
110. Millward TA, Zolnierowicz S, Hemmings BA. Regulation of protein kinase cascades by protein phosphatase 2A. Trends Biochem Sci 24: 186-191 (1999). (Pubitemid 29348452)
111. de la Monte SM, Chen GJ, Rivera E, Wands JR. Neuronal thread protein regulation and interaction with microtubule-associated proteins in SH-Sy5y neuronal cells. Cell Mol Life Sci 60: 2679-2691 (2003). (Pubitemid 38041368)
112. Lesort M, Johnson GV. Insulin-like growth factor-1 and insulin mediate transient site-selective increases in tau phosphorylation in primary cortical neurons. Neuroscience 99: 305-316 (2000). (Pubitemid 30628418)
113. Lesort M, Jope RS, Johnson GV. Insulin transiently increases tau phosphorylation: involvement of glycogen synthase kinase-3beta and Fyn tyrosine kinase. J Neurochem 72: 576-584 (1999). (Pubitemid 29055219)
114. Hong M, Lee VM. Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem 272: 19547-19553 (1997). (Pubitemid 27337756)
115. Meske V, Albert F, Ohm TG. Coupling of mammalian target of rapamycin with phosphoinositide 3-kinase signaling pathway regulates protein phosphatase 2A- and glycogen synthase kinase-3 - dependent phosphorylation of Tau. J Biol Chem 283: 100-109 (2008).
116. Cheng CM, Tseng V, Wang J, Wang D, Matyakhina L, Bondy CA. Tau is hyperphosphorylated in the insulin-like growth factor-I null brain. Endocrinology 146: 5086-5091 (2005). (Pubitemid 41653021)
117. Clodfelder-Miller BJ, Zmijewska AA, Johnson GV, Jope RS. Tau is hyperphosphorylated at multiple sites in mouse brain in vivo after streptozotocin-induced insulin deficiency. Diabetes 55: 3320-3325 (2006).
118. Planel E, Tatebayashi Y, Miyasaka T, Liu L, Wang L, Herman M, et al. Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms. J Neurosci 27: 13635-13648 (2007).
119. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325: 733-736 (1987).
120. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286: 735-741 (1999).
121. Lorenzo A, Yankner BA. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci USA 91: 12243-12247 (1994). (Pubitemid 24368641)
122. Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M, et al. Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci USA 96: 3922-3927 (1999).
123. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 8: 79-84 (2005).
124. Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, et al. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 402: 537-540 (1999).
125. De Strooper B. Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron 38: 9-12 (2003).
126. Holsinger RM, McLean CA, Beyreuther K, Masters CL, Evin G. Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann Neurol 51: 783-786 (2002). (Pubitemid 34568861)
127. Harada H, Tamaoka A, Ishii K, Shoji S, Kametaka S, Kametani F, et al. Beta-site APP cleaving enzyme 1 (BACE1) is increased in remaining neurons in Alzheimer's disease brains. Neurosci Res 54: 24-29 (2006).
128. Costantini C, Scrable H, Puglielli L. An aging pathway controls the TrkA to p75NTR receptor switch and amyloid beta-peptide generation. EMBO J 25: 1997-2006 (2006).
129. Puglielli L. Aging of the brain, neurotrophin signaling, and Alzheimer's disease: is IGF1-R the common culprit? Neurobiol Aging 29: 795-811 (2008).
130. Puglielli L, Ellis BC, Saunders AJ, Kovacs DM. Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. J Biol Chem 278: 19777-19783 (2003). (Pubitemid 36799164)
131. Sotthibundhu A, Sykes AM, Fox B, Underwood CK, Thangnipon W, Coulson EJ. Beta-amyloid(1-42) induces neuronal death through the p75 neurotrophin receptor. J Neurosci 28: 3941-3946 (2008).
132. Hsu AL, Murphy CT, Kenyon C. Regulation of aging and age-related disease by DAF-16 and heat-shock factor. Science 300: 1142-1145 (2003). (Pubitemid 36583098)
133. Ogg S, Paradis S, Gottlieb S, Patterson GI, Lee L, Tissenbaum HA, et al. The Fork head transcription factor DAF-16 transduces insulin-like metabolic and longevity signals in C. elegans. Nature 389: 994-999 (1997). (Pubitemid 27485694)
134. Lin K, Dorman JB, Rodan A, Kenyon C. daf-16: An HNF-3/forkhead family member that can function to double the life-span of Caenorhabditis elegans. Science 278: 1319-1322 (1997). (Pubitemid 27495748)
135. Lee RY, Hench J, Ruvkun G. Regulation of C. elegans DAF-16 and its human ortholog FKHRL1 by the daf-2 insulin-like signaling pathway. Curr Biol 11: 1950-1957 (2001). (Pubitemid 33146421)
136. Birkenkamp KU, Coffer PJ. Regulation of cell survival and proliferation by the FOXO (Forkhead box, class O) subfamily of Forkhead transcription factors. Biochem Soc Trans 31: 292-297 (2003). (Pubitemid 36241447)
137. Kimura KD, Tissenbaum HA, Liu Y, Ruvkun G. daf-2, an insulin receptor-like gene that regulates longevity and diapause in Caenorhabditis elegans. Science 277: 942-946 (1997). (Pubitemid 27366677)
138. Kenyon C, Chang J, Gensch E, Rudner A, Tabtiang R. A. C. elegans mutant that lives twice as long as wild type. Nature 366: 461-464 (1993).
139. Tu MP, Epstein D, Tatar M. The demography of slow aging in male and female Drosophila mutant for the insulin-receptor substrate homologue chico. Aging Cell 1: 75-80 (2002).
140. Clancy DJ, Gems D, Harshman LG, Oldham S, Stocker H, Hafen E, et al. Extension of life-span by loss of CHICO, a Drosophila insulin receptor substrate protein. Science 292: 104-106 (2001).
141. Giannakou ME, Goss M, Jacobson J, Vinti G, Leevers SJ, Partridge L. Dynamics of the action of dFOXO on adult mortality in Drosophila. Aging Cell 6: 429-438 (2007). (Pubitemid 47087049)
142. Coschigano KT, Holland AN, Riders ME, List EO, Flyvbjerg A, Kopchick JJ. Deletion, but not antagonism, of the mouse growth hormone receptor results in severely decreased body weights, insulin, and insulin-like growth factor I levels and increased life span. Endocrinology 144: 3799-3810 (2003). (Pubitemid 37088732)
143. Flurkey K, Papaconstantinou J, Miller RA, Harrison DE. Lifespan extension and delayed immune and collagen aging in mutant mice with defects in growth hormone production. Proc Natl Acad Sci USA 98: 6736-6741 (2001).
144. Gomez JM. Growth hormone and insulin-like growth factor-I as an endocrine axis in Alzheimer's disease. Endocr Metab Immune Disord Drug Targets 8: 143-151 (2008).
145. Brown-Borg HM, Borg KE, Meliska CJ, Bartke A. Dwarf mice and the ageing process. Nature 384: 33 (1996). (Pubitemid 26374577)
146. Selman C, Lingard S, Choudhury AI, Batterham RL, Claret M, Clements M, et al. Evidence for lifespan extension and delayed age-related biomarkers in insulin receptor substrate 1 null mice. FASEB J 22: 807-818 (2008).
147. Holzenberger M. The role of insulin-like signalling in the regulation of ageing. Horm Res 62 (Suppl 1): 89-92 (2004). (Pubitemid 40529156)
148. Taguchi A, Wartschow LM, White MF. Brain IRS2 signaling coordinates life span and nutrient homeostasis. Science 317: 369-372 (2007).
149. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120: 885-890 (1984). (Pubitemid 14104991)
150. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356 (2002). (Pubitemid 34790756)
151. Tanzi RE, Moir RD, Wagner SL. Clearance of Alzheimer's Abeta peptide: the many roads to perdition. Neuron 43: 605-608 (2004). (Pubitemid 39179722)
152. Zhao L, Teter B, Morihara T, Lim GP, Ambegaokar SS, Ubeda OJ, et al. Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention. J Neurosci 24: 11120-11126 (2004).
153. Carro E, Trejo JL, Spuch C, Bohl D, Heard JM, Torres-Aleman I. Blockade of the insulin-like growth factor I receptor in the choroid plexus originates Alzheimer's-like neuropathology in rodents: new cues into the human disease? Neurobiol Aging 27: 1618-1631 (2006).
154. Lanz TA, Salatto CT, Semproni AR, Marconi M, Brown TM, Richter KE, et al. Peripheral elevation of IGF-1 fails to alter Abeta clearance in multiple in vivo models. Biochem Pharmacol 75: 1093-1103 (2008).
155. Suh Y, Atzmon G, Cho MO, Hwang D, Liu B, Leahy DJ, et al. Functionally significant insulin-like growth factor I receptor mutations in centenarians. Proc Natl Acad Sci USA 105: 3438-3442 (2008).
156. Ho L, Qin W, Pompl PN, Xiang Z, Wang J, Zhao Z, et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 18: 902-904 (2004).
157. Cao D, Lu H, Lewis TL, Li L. Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. J Biol Chem 282: 36275-36282 (2007).
158. Ball MJ. Alzheimer's disease: a challenging enigma. Arch Pathol Lab Med 106: 157-162 (1982).
159. Torres-Aleman I. Targeting insulin-like growth factor-1 to treat Alzheimer's disease. Expert Opin Ther Targets 11: 1535-1542 (2007). (Pubitemid 350285003)
160. Ryan CM, Guoguang M, Peng Y, Cyparska A. A randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of MK-0677 25 mg in